This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Exploring SpringWorks Therapeutics' Phase 3 KOMET trial results evaluating Koselugo (selumetinib) in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibroma.
Ticker(s): SWTXWho's the expert?
Institution: NYU Langone Health
Pediatric neurologist and neuro-oncologist at the Stephen D. Hassenfeld Children’s Center, specializing in brain and spinal cord tumors and long-term survivorship care
Associate Director of the Comprehensive Neurofibromatosis Center; manages NF1, NF2, and schwannomatosis in patients of all ages
Actively involved in clinical trials and translational research, offering patients access to cutting-edge treatments in pediatric neuro-oncology
Interview GoalOn this call we will be discussing the primary results from the KOMET Phase 3 trial (NCT04924608) presented at ASCO, evaluating Koselugo (selumetinib) in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
